After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...
IGF-1 levels remained stable at week 96 for PATHFNDR-1 patients switched to oral palsonify. Daily symptom flares dropped from over 30% on injectables to 6.2% with palsonify in PATHFNDR-1. Get a Year ...
SAN FRANCISCO—People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved paltusotine for first-line treatment of patients with acromegaly who did not respond to or ...
Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the ...
Credit: Crinetics. Palsonify is supplied as a 20mg and 30mg tablet. Palsonify is an oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist. The Food and Drug Administration (FDA) ...
Bone health is critically influenced by the balance of growth hormone signalling, with both growth hormone deficiency (GHD) and acromegaly demonstrating significant but contrasting impacts on the ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on ...
A 23-year-old man was admitted to the hospital with severe dyspnoea, elevated body temperature, and rhinorrhoea. Several endocrinological disorders were known in the patient’s family. Echocardiography ...
We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies that soared by double- and triple-digits last ...
"September 25, 2025 was a historic day for Crinetics with the approval of Palsonify for the treatment of people with acromegaly,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback